Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.

Mol Oncol · 2023 · PMC10158763 · PMID 36852704

Europe PMC DOI

hedged sentences

0.0938

closest p · 1.9× alpha

0.1800

boldest claim

The sentences

did not reach statistical significanceP = 0.0938so close (0.05 < p ≤ 0.1)

When we compared patients with durable clinical benefit (DCB) to those with no durable benefit (NDB), TFx was higher in the latter group, although it did not reach statistical significance (Mann–Whitney Wilcoxon, P = 0.0938; Fig. 2C ).

also in 111,027 other papers

a nonsignificant trendP = 0.18not close (p > 0.1)

When considering two groups of patients, those with detectable ctDNA and those with undetectable ctDNA, there was a nonsignificant trend toward inferior PFS and overall survival (OS) in those patients with the former (Log rank test, P = 0.18, Fig. 2B ; Log rank test, P = 0.22, Fig.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.